Change at the top for Biogen after Alzheimer’s drug flops

May 3, 2022, 4:39 AM | Updated: 10:57 am
The Biogen Inc., headquarters, March 11, 2020, in Cambridge, Mass. Biogen is looking for a new CEO,...

The Biogen Inc., headquarters, March 11, 2020, in Cambridge, Mass. Biogen is looking for a new CEO, less than a year after its launch of its Alzheimer's drug Aduhelm largely fizzled. The company said Tuesday, May 3, 2022 that current CEO Michel Vounatsos will continue to lead the company until his successor is appointed. (AP Photo/Steven Senne, file)

(AP Photo/Steven Senne, file)

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less than a year after the medication’s launch triggered a backlash from experts, doctors and insurers.

CEO Michel Vounatsos will continue to lead the Biogen until a successor is found, the company announced Tuesday. Vounatsos joined the company in 2016 and was the chief architect of Biogen’s strategy built around Aduhelm.

For now, Biogen said it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company’s flagging biotech business.

The announcement represents a stark acknowledgement that the Cambridge, Massachusetts-based company has failed to find a market for a drug that was expected to drive its business for years to come.

Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster drug that would generate billions for Biogen.

But doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage over the drug’s high price tag and uncertain benefit. Even the company’s decision to slash the drug’s price in half– to $28,000 a year — did little to improve uptake.

The biggest setback came last month when the federal government’s Medicare health plan imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. The vast majority of U.S. Alzheimer’s patients are old enough to qualify for Medicare, which covers more than 60 million people, including those 65 and older.

The infused drug brought in just $2.8 million in sales in the first quarter, which ended March 31.

Biogen said Tuesday that it booked about $275 million in charges from Aduhelm inventory write-offs in the quarter, and it would essentially shutdown its sales and marketing infrastructure supporting the drug.

Aduhelm expenses dragged down the company’s quarterly results and Biogen fell short of Wall Street projections, reporting adjusted net income of $535 million, or $3.62 per share. Analysts forecast earnings of $4.34 per share, according to FactSet.

Biogen executives said the restrictive Medicare decision essentially denied Aduhelm to most eligible U.S. patients. Last month the company announced it was pulling its marketing application for the drug in Europe.

Biogen will continue running a federally-mandated confirmatory trial designed to establish if the drug truly slows Alzheimer’s.

The drugmaker’s quarterly revenue fell 6% to $2.5 billion, pressured by lower sales of multiple sclerosis drugs in the U.S. due to cheaper, generic competition. The company also reported lower sales of its specialty drug Spinraza, which is used to treat a rare spinal disorder in children.

For the year, Biogen reaffirmed earnings guidance of between $14.25 and $16.00 per share.

Biogen executives said they will continue pursuing new Alzheimer’s treatments including a drug similar to Aduhelm. Researchers are awaiting last-stage testing results for the drug in the fall. But the company also highlighted other drugs in its pipeline, including potential treatments for depression and schizophrenia.

Vounatsos departure was expected “given the many setbacks the company has faced,” RBC Capital Markets analyst Brian Abrahams wrote Tuesday. The move and reorganization “will be well received over the long term, and give the company a fresh start in refocusing R&D priorities.”

Shares of Biogen Inc. rose less than 1%.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Finland's Foreign Minister Pekka Haavisto, left, Sweden's Foreign Minister Ann Linde, right, and NA...
Associated Press

Finland to boost security at Russia border with amended law

HELSINKI (AP) — Finland’s Parliament on Thursday passed amended legislation on border security that allows for the closure of crossing points with Russia amid fears that Moscow could choose to send large numbers of migrants to the frontier. The move by lawmakers came just two days after NATO’s 30 members signed formal accession protocols for […]
10 hours ago
Firefighters hose down a burning car after a strike hit a residential area, in Kramatorsk, Donetsk ...
Associated Press

Russia taking ‘operational pause’ in Ukraine, analysts say

Analysts say Russia may be taking an "operational pause" in eastern Ukraine to reassemble forces for a significant offensive.
10 hours ago
A memorial to the seven people killed and others injured in Monday's Fourth of July mass shooting g...
Associated Press

Red flags missed: How July 4 suspect slipped through system

Illinois’ “red-flag” law could have stopped, or at least slowed down, the suspect in the Independence Day parade shooting from being able to buy the gun he is accused of using to kill seven people and wound dozens more. Police in the Chicago suburb of Highland Park were called twice to the home of Robert […]
10 hours ago
Associated Press

EU decision on natural gas could threaten climate progress

The European Union’s decision to include natural gas in a list of activities considered sustainable could derail its progress in reducing greenhouse gas emissions at a time when climate scientists are calling for dramatic reductions to planet-warming releases. The decision, reached Wednesday, will allow investment in natural gas infrastructure such as natural gas power plants […]
10 hours ago
FILE - In this Feb. 27, 2008 file photo, euro coins and dollar bills are seen in Frankfurt, central...
Associated Press

With US dollar nearly equal to euro, impact is being felt

WASHINGTON (AP) — The U.S. dollar has been surging so much that it’s nearly equal in value to the euro for the first time in 20 years. That trend, though, threatens to hurt American companies because their goods become more expensive for foreign buyers. If U.S. exports were to weaken as a result, so, too, […]
10 hours ago
Associated Press

Italy seeks to bring home family whose son died in Egypt

ROME (AP) — The Italian Foreign Ministry said Thursday it is working to quickly bring back from Egypt an Italian family whose 6-year-old son died suddenly in the Red Sea resort of Sharm el-Sheikh and the parents ended up hospitalized. Italian news reports said the child was believed to have suffered from a suspected case […]
10 hours ago

Sponsored Articles

(Courtesy Condor)...
Condor Airlines

Condor Airlines shows passion for destinations from Sky Harbor with new-look aircraft

Condor Airlines brings passion to each flight and connects people to their dream destinations throughout the world.
...
Arizona Division of Problem Gambling

Arizona Division of Problem Gambling provides exclusion solution for young sports bettors

Sports betting in Arizona opened a new world to young adults, one where putting down money on games was as easy as sending a text message.
...
Carla Berg, MHS, Deputy Director, Public Health Services, Arizona Department of Health Services

ADHS mobile program brings COVID-19 vaccines and boosters to Arizonans

The Arizona Department of Health Services and partner agencies are providing even more widespread availability by making COVID-19 vaccines available in neighborhoods through trusted community partners.
Change at the top for Biogen after Alzheimer’s drug flops